<DOC>
	<DOCNO>NCT00678327</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure , fludeoxyglucose F 18 ( FDG ) -PET/CT scan , do , , chemotherapy may help doctor assess patient 's response treatment help plan best treatment . It yet know whether FDG-PET/CT image effective assess response chemotherapy patient newly diagnose Hodgkin lymphoma . PURPOSE : This randomized phase III trial study FDG-PET/CT imaging see well work assess response chemotherapy patient newly diagnose stage II , stage III , stage IV Hodgkin lymphoma .</brief_summary>
	<brief_title>Fludeoxyglucose F 18-PET/CT Imaging Assessing Response Chemotherapy Patients With Newly Diagnosed Stage II , Stage III , Stage IV Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - To determine fludeoxyglucose F 18 ( FDG ) -PET/CT image reproducibly effectively apply early assessment response chemotherapy patient newly diagnose stage II-IV Hodgkin lymphoma . - To determine negative FDG-PET/CT scan 2 course ABVD chemotherapy comprise doxorubicin hydrochloride , bleomycin , vinblastine , dacarbazine use predict group patient safe reduce therapy subsequent omission bleomycin , without detriment progression-free survival . - To determine treatment intensification response positive FDG-PET/CT image 2 course ABVD chemotherapy improve outcome comparison previous series . OUTLINE : This multicenter study . Patients undergo fludeoxyglucose F 18 ( FDG ) -PET/CT image baseline . Patients receive ABVD chemotherapy comprise doxorubicin hydrochloride IV , bleomycin IV , vinblastine IV , dacarbazine IV day 1 15 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . Between day 22 25 course 2 , patient undergo second FDG-PET/CT scan ass response . Subsequent therapy base FDG-PET/CT scan result . - Negative FDG-PET/CT scan : Patients negative FDG-PET/CT scan randomize 1 2 treatment arm . - Arm I ( ABVD chemotherapy ) : Patients receive ABVD chemotherapy comprise doxorubicin hydrochloride IV , bleomycin IV , vinblastine IV , dacarbazine IV day 1 15 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . - Arm II ( AVD chemotherapy ) : Patients receive AVD chemotherapy comprise doxorubicin hydrochloride IV , vinblastine IV , dacarbazine IV day 1 15 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . - Positive FDG-PET/CT scan : Patients positive FDG-PET/CT scan assign 1 2 chemotherapy regimen , determine participate center . - BEACOPP-14 chemotherapy : Patients receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 ; etoposide IV day 1-3 ; oral procarbazine hydrochloride oral prednisolone day 1-7 ; bleomycin IV vincristine IV day 8 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) day 8-13 OR pegfilgrastim SC day 8 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . - BEACOPP-escalated chemotherapy : Patients receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 ; etoposide IV day 1-3 ; oral procarbazine hydrochloride day 1-7 ; oral prednisolone day 1-14 ; bleomycin IV vincristine IV day 8 . Patients also receive G-CSF SC begin day 8 continue blood count recover OR pegfilgrastim SC day 8 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . After completion BEACOPP chemotherapy , patient undergo third FDG-PET/CT scan ass response . Patients negative FDG-PET/CT scan receive 2 course BEACOPP-14 1 course BEACOPP-escalated chemotherapy . Patients persistently positive FDG-PET/CT scan may receive radiotherapy site FDG uptake salvage chemotherapy , investigator 's discretion . After completion study therapy , patient follow every 3 month 1 year , every 4 month 2 year , every 6 month 2 year , annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm classical Hodgkin lymphoma ( HL ) meeting follow criterion : Meets current WHO classification criterion ( i.e. , nodular sclerosis , mixed cellularity , lymphocyte rich , lymphocytedepleted ) Clinical stage IIB , III , IV disease OR clinical stage IIA disease adverse feature , include follow : Bulk mediastinal disease , define maximal transverse diameter mass &gt; 0.33 internal thoracic diameter D5/6 interspace routine chest xray Disease outside mediastinum lymph node lymph node mass &gt; 10 cm diameter More two site disease Other poorrisk feature require treatment full course combination chemotherapy Newly diagnose disease No CNS meningeal involvement lymphoma PATIENT CHARACTERISTICS : ECOG performance status 03 Life expectancy &gt; 3 month ANC &gt; 1,500/mm^3 ( unless bone marrow infiltration lymphoma ) Platelet count &gt; 100,000/mm^3 ( unless bone marrow infiltration lymphoma ) Creatinine &lt; 150 % upper limit normal ( ULN ) Bilirubin &lt; 2.0 time ULN ( unless attribute lymphoma ) Transaminases &lt; 2.5 time ULN ( unless attribute lymphoma ) LVEF â‰¥ 50 % ( patient significant history ischemic heart disease hypertension ) Diffusion capacity within 25 % normal predict value lung function test Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Amenable administration full course chemotherapy , accord investigator Must access PET/CT scan No poorly control diabetes mellitus No cardiac contraindication doxorubicin hydrochloride , include abnormal contractility ECHO MUGA No neurological contraindication chemotherapy ( e.g. , preexist neuropathy ) No concurrent uncontrolled medical condition No active malignant disease within past 10 year , except fully excise basal cell squamous cell carcinoma skin carcinoma situ uterine cervix No known positivity HIV , hepatitis B surface antigen , hepatitis C Routine testing , absence risk factor , require No medical psychiatric condition compromise patient 's ability give inform consent PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy investigational drug HL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
</DOC>